Skip to main content

ORIGINAL RESEARCH article

Front. Public Health

Sec. Health Economics

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1538789

A Cost Analysis of Reductions in Work Productivity for MG Patients and their Caregivers by Symptom Severity

Provisionally accepted
Sarah Dewilde Sarah Dewilde 1*Cynthia Qi Cynthia Qi 2Femke De Ruyck Femke De Ruyck 3Sandra Paci Sandra Paci 3Lucas Van de Veire Lucas Van de Veire 1Alison Griffiths Alison Griffiths 1Gil Wolfe Gil Wolfe 4Renato Mantegazza Renato Mantegazza 5Glenn Phillips Glenn Phillips 2
  • 1 Services in Health Economics, Brussels, Belgium
  • 2 Argenx US Inc., Boston, Massachusetts, United States
  • 3 argenx BVBA, Zwijnaarde, Belgium
  • 4 Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Baffalo, New York, United States
  • 5 IRCCS Carlo Besta Neurological Institute Foundation, Milan, Lombardy, Italy

The final, formatted version of the article will be published soon.

    Myasthenia Gravis (MG) is a debilitating autoimmune disorder associated with fatigue and weakness in the ocular, respiratory, bulbar and limb muscles. This study evaluates productivity losses for MG patients and their caregivers by MG symptom severity.In the multinational MyRealWorld-MG study, 1049 MG patients and caregivers reported on work productivity (sick leave, reduced working hours, early retirement). Productivity losses were calculated using the average wage per hour. A UK perspective was adopted for the whole sample, and country-specific analyses were conducted for Italy, Spain and the US. The MG-Activities of Daily Living (MG-ADL) score was used to estimate the association between symptom severity and productivity losses, with patients categorized as having mild (0-4), moderate (5-9), or severe (>=10) symptoms.In the MyRealWorld-MG study, 36.5% MG patients reported taking sick leave within the last month and 11.4% reported stopping work (or retiring early) due to MG. Furthermore, 36.0% required caregiver support with 14.6% of caregivers reducing working hours and 13.4% stopping work. Mean productivity losses were £16,630/year for patients and caregivers combined, largely attributable to patient productivity losses (£13,891). Patients with severe MG incurred 3.8 times more productivity losses compared to patients with mild disease. Productivity loss estimates varied between Italy, Spain and the US.The impact of MG on patients' and caregivers' work productivity leads many of them to reduce work hours or retire early, resulting in significant productivity losses. The magnitude of these productivity losses is correlated with symptom severity and varies by country.

    Keywords: ADAPT, Caregivers, Costs, efgartigimod, GMG, Generalized Myasthenia Gravis, MyRealWorld-MG, productivity losses

    Received: 03 Dec 2024; Accepted: 03 Mar 2025.

    Copyright: © 2025 Dewilde, Qi, De Ruyck, Paci, Van de Veire, Griffiths, Wolfe, Mantegazza and Phillips. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Sarah Dewilde, Services in Health Economics, Brussels, Belgium

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more